纳武利尤单抗对比安慰剂辅助治疗已切除黑色素瘤的间接治疗比较
本研究采用Bucher法间接治疗比较,利用CheckMate 238和EORTC 18071两项III期试验的意向治疗人群数据,比较纳武利尤单抗与安慰剂(代表观察等待策略)在高危已切除黑色素瘤患者中的疗效。结果显示,纳武利尤单抗对比安慰剂在无复发生存期(RFS)、远处转移无生存期(DMFS)和总生存期(OS)方面均带来临床有意义的改善。
要点
- 纳武利尤单抗对比安慰剂显著改善RFS(HR 0.53,95%CI 0.42-0.68)和OS(HR 0.63,95%CI 0.45-0.89)。
- 在IIIB/IIIC期患者中,纳武利尤单抗对比安慰剂亦改善RFS、DMFS和OS。
- 调整复发后生存后,总体人群OS仍 favoring 纳武利尤单抗(HR 0.65,95%CI 0.46-0.92)。
核心结论
- 间接治疗比较显示,辅助纳武利尤单抗对比观察等待策略在高危已切除黑色素瘤中带来临床有意义的RFS、DMFS和OS改善。
研究设计与样本
- 采用Bucher法进行间接治疗比较,使用CheckMate 238(纳武利尤单抗 vs 伊匹木单抗,最少随访4年)和EORTC 18071(伊匹木单抗 vs 安慰剂,最少随访约4.5年)的意向治疗人群数据。
主要发现
- 纳武利尤单抗对比安慰剂:RFS的HR为0.53(95%CI 0.42-0.68),OS的HR为0.63(95%CI 0.45-0.89)。
- IIIB/IIIC期患者中,纳武利尤单抗对比安慰剂:RFS的HR为0.53(95%CI 0.40-0.69),DMFS的HR为0.62(95%CI 0.46-0.83),OS的HR为0.67(95%CI 0.47-0.97)。
- 调整EORTC 18071中复发后生存后,总体人群OS的HR为0.65(95%CI 0.46-0.92)。
临床怎么用
- 对于高危已切除黑色素瘤患者,辅助纳武利尤单抗相比观察等待策略可改善无复发生存、远处转移无生存和总生存。
局限性
- 为间接治疗比较,非头对头证据;需考虑跨试验在分期和后续治疗方面的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab (an anti-programmed death-1 antibody) is an adjuvant standard of care for patients with high-risk resected melanoma, although a watch-and-wait strategy remains an option. In the absence of head-to-head evidence, an indirect treatment comparison (ITC) of adjuvant nivolumab versus placebo, the proxy for a watch-and-wait strategy, was conducted in patients with high-risk resected melanoma. METHODS: An ITC using the Bucher method compared nivolumab with placebo using intention-to-treat population data from the phase III CheckMate 238 (nivolumab vs ipilimumab; minimum follow-up, 4 years; NCT02388906) and European Organisation for Research and Treatment of Cancer (EORTC) 18071 (ipilimumab vs placebo; minimum follow-up, ≈4.5 years; NCT00636168) trials. The end-points were recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS). To account for cross-trial differences in staging and subsequent therapy, additional analyses examined patients with stage IIIB/IIIC disease and adjusted post-recurrence survival in EORTC 18071, respectively. RESULTS: Nivolumab versus placebo was associated with clinically meaningful improvements in RFS (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.42-0.68) and OS (HR, 0.63; 95% CI, 0.45-0.89). Nivolumab versus placebo was also associated with clinically meaningful improvements in RFS (HR, 0.53; 95% CI, 0.40-0.69), DMFS (HR, 0.62; 95% CI, 0.46-0.83) and OS (HR, 0.67; 95% CI, 0.47-0.97) in patients with stage IIIB/IIIC disease and in OS (HR, 0.65; 95% CI, 0.46-0.92) in the overall population after adjusting post-recurrence survival in EORTC 18071. CONCLUSION: This ITC shows that adjuvant nivolumab provides clinically meaningful improvements in RFS, DMFS and OS versus a watch-and-wait strategy in high-risk resected melanoma.
引用
- Weber JS, Ascierto PA, Middleton MR, et al. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. Eur J Cancer. 2021. PMID: 34663559. doi:10.1016/j.ejca.2021.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。